FDA approves durvalumab with enfortumab vedotin for muscle-invasive bladder cancer
FDA approval · FDA · 2026-11-13. Number 1 in the UrologyWatch Top 5 for November 15, 2026.
FDA approved the perioperative combination of durvalumab (an immune checkpoint inhibitor) and enfortumab vedotin-ejfv for muscle-invasive bladder cancer.
Why it matters: Adds a new FDA-approved perioperative regimen option for muscle-invasive bladder cancer.
Source: FDA
Loading today's edition…